CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

A doctor may prescribe ketorolac (Toradol), an NSAID available as a nasal spray, to help manage migraine attacks that cause severe pain. They may also recommend ketorolac as a rescue medication if ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

PH284 nasal spray increased hunger in cancer cachexia patients, showing a 71% improvement in subjective hunger scores compared to baseline. The phase 2A study demonstrated PH284's safety, with no ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...